"Lithuania Pharmaceuticals & Healthcare Report Q4 2015" Published

Continued price cuts to pharmaceuticals and the spill over effect from the downturn in the Russian economy will continue to have an impact on the Lithuanian pharmaceutical market. Nevertheless, rising wages and falling food prices will support growth in spending on consumer healthcare products, namely OTC medicines.

Headline Expenditure Projections

Pharmaceuticals: EUR601mn (USD806mn) in 2014 to EUR618mn(USD680mn) in 2015; +2.7% in local currency terms and -15.7% in US dollar terms. Forecast revised downwards from Q215.
Healthcare: EUR2.14bn (USD2.87bn) in 2014 to EUR2.15bn (USD2.36bn) in 2015; +0.3% in local currency terms and -17.6% in US dollar terms. Forecast revised downwards from Q215.

Full Report Details at
- http://www.fastmr.com/prod/1052955_lithuania_pharmaceuticals.aspx?afid=302

Risk/Reward Index

Lithuania has a Risk/Reward Index (RRI) score of 48.0 out of 100, making it the 13th most attractive pharmaceutical market in Central and Eastern Europe. Lithuania scores below the regional average score of 49.5 in Q315. Lithuania scores (13.6 below the regional average for Industry Rewards (16.9), with the country's limited size holding back its score. Lithuania's overall Reward score of 26.6 is below the regional average (29.8), highlighting the limited growth outlook for pharmaceuticals and the small overall size of the Lithuanian market.

Key Trends and Developments

In May 2015, Lithuania's healthcare system completed a pilot of a nationwide electronic prescription system. Backend functions of the new system were also tested in medical institutions, highlighting the progress that Lithuania is making in transitioning to e-health services.

In April 2015, prices of reimbursed medicines were revised by the Ministry of Health, with almost 1300 medicines seeing their prices reduced and seven drugs seeing price hikes. The new prices will save the health insurance fund some EUR9mn (USD9.54mn) in 2015.

The Lithuania Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Lithuania Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Lithuania pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Lithuania, to test other views - a key input for successful budgeting and strategic business planning in the Lithuanian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Lithuanian pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015